— Know what they know.
Not Investment Advice

COG.L LSE

Cambridge Cognition Holdings Plc
1W: -1.7% 1M: -11.2% 3M: -17.9% YTD: -29.4% 1Y: +5.8% 3Y: -70.1% 5Y: -82.5%
£27.52 ($0.36)
-0.48 (-1.71%)
 
Weekly Expected Move ±4.1%
£25 £26 £28 £29 £30
LSE · Healthcare · Medical - Healthcare Information Services · Tech Score Sell · Power 37 · £15.1M mcap · 34M float · 0.086% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap£15.1M ($0.2M)
52W Range26.6-45
Volume3,634
Avg Volume29,022
Beta0.81
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORobert Baker
Employees74
SectorHealthcare
IndustryMedical - Healthcare Information Services
IPO Date2013-04-18
Tunbridge Court
Cambridge, CAM CB25 9TU
GB
44 1223 810 700
About Cambridge Cognition Holdings Plc

Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms